We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

35 hedge funds and large institutions have $23M invested in Cymabay Therapeutics in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 2

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

27% more capital invested

Capital invested by funds: $18.2M → $23M (+$4.81M)

21% more funds holding

Funds holding: 29 → 35 (+6)

Holders
35
Holders Change
+6
Holders Change %
+20.69%
% of All Funds
0.98%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
13
Increased
11
Reduced
2
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
+$4.36M
2
KCM
Kingdon Capital Management
New York
+$2.59M
3
AC
Armistice Capital
New York
+$2.28M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.91M
5
OFM
Omega Fund Management
Massachusetts
+$1.77M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$2.31M
2
EAM
EverPoint Asset Management
Connecticut
-$1.26M
3
VAM
Visium Asset Management
New York
-$626K
4
ARTA
A.R.T. Advisors
New York
-$97K
5
PP
PDT Partners
New York
-$75K
Name Holding Trade Value Shares
Change 		Change in
Stake
TC
26
TFS Capital
Pennsylvania
$41K +$57.9K +21,263 New
ACI
27
Alpha Cubed Investments
California
$31K – – –
Balyasny Asset Management
28
Balyasny Asset Management
Illinois
$24K -$4.67K -1,715 -12%
Creative Planning
29
Creative Planning
Kansas
$23K +$32.7K +12,000 New
Mariner
30
Mariner
Kansas
$23K +$32.7K +12,000 New
Walleye Trading
31
Walleye Trading
New York
$8K +$11.2K +4,100 New
BIM
32
BlackRock Investment Management
Delaware
$6K +$2.48K +912 +41%
Morgan Stanley
33
Morgan Stanley
New York
$5K – – –
Bank of America
34
Bank of America
North Carolina
$4K – – –
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1 – – –
Jennison Associates
36
Jennison Associates
New York
– -$2.31M -858,786 Closed
EAM
37
EverPoint Asset Management
Connecticut
– -$1.26M -468,099 Closed
ARTA
38
A.R.T. Advisors
New York
– -$97K -36,069 Closed
PP
39
PDT Partners
New York
– -$75K -27,900 Closed
JP Morgan Chase
40
JP Morgan Chase
New York
– -$67K -25,000 Closed
SIM
41
Spark Investment Management
New York
– -$30K -11,300 Closed
UBS Group
42
UBS Group
Switzerland
– -$18K -6,771 Closed
1
2

CBAY Hedge Fund Activity: Q3 2015 in Review

35 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2015, worth a combined $23M — up 27% from $18.2M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CBAY positions and 7 closed out — a net gain of 6 holders — while 11 added to existing stakes and 2 trimmed.

The largest buyer was Abingworth, opening a new position worth an estimated $4.36M. The largest seller was Jennison Associates, exiting entirely with an estimated $2.31M sold.

  • 35 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2015, up from 29 in Q2 2015.
  • Funds reported $23M of Cymabay Therapeutics stock for Q3 2015, up 27% quarter-over-quarter.
  • 13 funds opened new Cymabay Therapeutics positions in Q3 2015 and 7 closed out, a net change of +6 holders.
  • The largest Cymabay Therapeutics buyer in Q3 2015 was Abingworth, an estimated $4.36M added.
  • The largest Cymabay Therapeutics seller in Q3 2015 was Jennison Associates, an estimated $2.31M sold.

Based on aggregated 13F filings for Q3 2015.